1. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. (2nd June 2021) Authors: Ferrante, Marc; Feagan, Brian G; Panés, Julián; Baert, Filip; Louis, Edouard; Dewit, Olivier; Kaser, Arthur; Duan, W Rachel; Pang, Yinuo; Lee, Wan-Ju; Gustafson, Dawn; Liao, Xiaomei; Wallace, Kori; Kalabic, Jasmina; D'Haens, Geert R Journal: Journal of Crohn's and colitis Issue: Volume 15:Number 12(2021) Page Start: 2001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Issue 10340 (28th May 2022) Authors: D'Haens, Geert; Panaccione, Remo; Baert, Filip; Bossuyt, Peter; Colombel, Jean-Frederic; Danese, Silvio; Dubinsky, Marla; Feagan, Brian G; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James O; Loftus, Edward V; Panés, Julian; Peyrin-Biroulet, Laurent; Ran, Zhihua; Rubin, David T; Sandborn, William J... Journal: Lancet Issue: Volume 399:Issue 10340(2022) Page Start: 2015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Issue 10340 (28th May 2022) Authors: Ferrante, Marc; Panaccione, Remo; Baert, Filip; Bossuyt, Peter; Colombel, Jean-Frederic; Danese, Silvio; Dubinsky, Marla; Feagan, Brian G; Hisamatsu, Tadakazu; Lim, Allen; Lindsay, James O; Loftus, Edward V; Panés, Julián; Peyrin-Biroulet, Laurent; Ran, Zhihua; Rubin, David T; Sandborn, William J... Journal: Lancet Issue: Volume 399:Issue 10340(2022) Page Start: 2031 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S714 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn's Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction. (October 2022) Authors: D'Haens, Geert; Panaccione, Remo; Panés, Julian; Hisamatsu, Tadakazu; Bossuyt, Peter; Danese, Silvio; Neimark, Ezequiel; Song, Alexandra; Liao, Xiaomei; Wallace, Kori; Zambrano, Javier; Duan, W Rachel; Kligys, Kristina Other Names: Dubinsky Marla presenter. Journal: American journal of gastroenterology Issue: Volume 117:Number 10(2022)supplement 10S Page Start: e497 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗